Melanoma research reaches a milestone
21 March 2017
Melanoma research has reached a milestone with the 10,000th patient giving their permission for their blood and tissue samples to be used in the world’s largest melanoma biospecimen bank.
Melanoma Institute Australia (MIA) has been collecting samples from melanoma patients since 1999 and now has an incredible resource that is powering melanoma research here and around the globe. Together with patient records, the samples add enormous value to the clinical stories of our patients and drive discovery and translational research that will, in turn, provide answers to the clinical questions plaguing our doctors.
“When a patient first presents to MIA, we don't have the crystal ball to predict what their journey is going to be like,” says Biospecimen Bank Manager, Valerie Jakrot (pictured). “We now know that melanoma is not just one disease, and so we must look at the molecular level to understand the differences between each type.”
Because of the large number of samples collected, MIA and collaborators from around the world have access to a wide variety of different types of melanoma, including some of the rarer forms, growing our understanding of the disease. In addition, a large number of samples are needed to test and confirm hypotheses in research, and so the Biospecimen Bank’s magnitude is invaluable.
Personalised medicine
By using the samples to identify which genes drive the disease, researchers will gain a better understanding to improve patient outcomes. This is the basis of personalised medicine.
“By finding out which genes are involved in causing a patient’s melanoma, we will be able to better predict the course of the disease and identify which treatment will be most effective for the patient,” says Valerie. “This knowledge will change the management of patients from the very beginning, ensuring the best possible outcome is reached.”
Collaborations
Biospecimen Bank samples have also been used in a number of key research projects, including the Australian Melanoma Genome Project, which is mapping the entire genome of 500 melanomas. Our samples have contributed significantly to The Cancer Genome Atlas (TCGA), a five year study of tumours from over 300 patients around the world. In addition, data has been made available to the International Cancer Genome Consortium (ICGC), which is seeking to understand the genetic causes of 50 different cancer types.
Contributions making a difference
As the largest collection of melanoma blood and tissue samples in the world, the Biospecimen Bank would not have been established without significant resources from MIA. Being a specialised treatment centre, MIA has access to a large number of patients who generously consent to being part of this endeavour. Without the support of our patients, and donors who see the long-term potential of this project, the Biospecimen Bank simply wouldn’t exist.
Melanoma research gets a funding boost from NHMRC
Research projects led by MIA have been awarded almost $6 million in the latest NHMRC funding round which will enable vital progression of research into melanoma prevention and treatment.
Challenges in melanoma clinical research
The last decade has seen a surge in therapeutic options for advanced melanoma patients, thanks to research. However, not every patient responds to treatment and researchers are taking on the challenge to find out why.
Global Melanoma Research Report
Our first Global Melanoma Research Report shares selected research from around the world and here at MIA that is making a difference to the lives of melanoma patients now and in the future.
Announcement from Melanoma Institute Australia
After 18 years as Director of the Sydney Melanoma Unit and then Executive Director of Melanoma Institute Australia, Professor John Thompson AO will step down from the position at the end of 2016.
Nine practice points from the new melanoma guidelines
Australian melanoma clinical practice guidelines have been published on a wiki platform for the first time as researchers try to keep up to date with emerging evidence.
Melanoma under 40
Carole Renouf, CEO of Melanoma Institute Australia is asking young Australians who have been affected by melanoma to share their experiences with her.
Don't let sunburn be your summer holiday souvenir
Melanoma Institute Australia CEO Carole Renouf wants to make sure Aussies remember to take care of our skin as the festive season draws closer and we spend more time in the sun.
Using clinical features to identify patients at high risk for melanoma
Can an individual’s risk factors for melanoma be used to tailor skin self-examinations and surveillance programs?
Congratulations to Professor Georgina Long
Prof Georgina Long has been appointed President-Elect Society for Melanoma Research (SMR).
Uniting our global researchers for melanoma
The Australasian Melanoma Conference is bringing together some of the world's leading researchers and clinicians.
Best practice guidelines for melanoma care go digital
Best practice guidelines for melanoma care have gone digital with the first-ever online guidelines developed to adapt to the rapid change in clinical management.
Awards and honours for our talented researchers
Congratulations are in order for two of our talented researchers.
5 Minutes With Prof Richard Scolyer
Professor Richard Scolyer will be sharing his expertise on melanoma pathology at the upcoming Australasian Melanoma Conference. Here he discusses what he'll be presenting on.
Research spotlight: High Risk Clinic
Researchers at MIA have established a High Risk Clinic to monitor people at very high risk of developing melanoma.
Learning from the best in the world
A generous donation has enabled a medical oncologist from Portugal to learn from the best in the world at MIA.
Uniting the world for a cure
MIA is hosting a conference to bring together greats minds in melanoma research that will make a difference to the lives of melanoma patients
A Day in the Life of... Michelle Peranec
Meet Michelle, our Translational Research Officer whose role is to connect the clinics to the lab by ensuring patient blood and tissue samples are documented and carefully stored in our BioSpecimen Bank.
Wildfire Award helps ignite new melanoma research
Dr James Wilmott says his Wildfire Award will help expand research into treatment options for people with mucosal melanoma, a rare but deadly form of skin cancer.
Opinion: Fighting the Resistance
Following the recent hype around immunotherapies in cancer, CEO Carole Renouf shares the greatest story never told… resistance… and what MIA is doing to address it.
5 Minutes With A/Prof Jennifer Wargo
A/Prof Wargo discusses the research she will be presenting as a keynote speaker at the upcoming Australasian Melanoma Conference.